hat
Flipanserin Hydrochloride yo itilize pou maladi ipoektif dezi seksyèl nan mitan fanm yo. Moun k ap resevwa Flokanserin Hydrochloride rapòte yon ogmantasyon 0.5 konpare ak plasebo nan kantite fwa yo te "satisfè evènman seksyèl". Nan moun ki sou flibanserin li leve soti nan 2.8 a 4.5 fwa yon mwa pandan y ap fanm k ap resevwa plasebo rapòte tou yon ogmantasyon de "satisfè evènman seksyèl" nan 2.7 a 3.7 fwa yon mwa. Te aparisyon nan efè a flibanserin wè nan premye tan an mezire apre 4 semèn nan tretman ak konsève pandan tout peryòd tretman an.
eng
Flibanserin Hydrochloride is used for hypoactive sexual desire disorder among women. Those receiving Flibanserin Hydrochloride report a 0.5 increase compared to placebo in the number of times they had "satisfying sexual events". In those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of "satisfying sexual events" from 2.7 to 3.7 times a month.The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.